File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.cbpa.2020.02.006
- Scopus: eid_2-s2.0-85081671186
- PMID: 32200302
- WOS: WOS:000534347400023
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Metalloproteomics in conjunction with other omics for uncovering the mechanism of action of metallodrugs: mechanism-driven new therapy development
Title | Metalloproteomics in conjunction with other omics for uncovering the mechanism of action of metallodrugs: mechanism-driven new therapy development |
---|---|
Authors | |
Keywords | Metalloproteomics Multi-omics Metallodrugs Mechanism of action Mechanism-driven new therapy development |
Issue Date | 2020 |
Publisher | Elsevier Ltd, Current Opinion Journals. The Journal's web site is located at http://www.elsevier.com/locate/cbi |
Citation | Current Opinion in Chemical Biology, 2020, v. 55, p. 171-179 How to Cite? |
Abstract | Medicinal inorganic chemistry has been largely stimulated by the clinic success of platinum anticancer drugs. An array of metal-based drugs (e.g. platinum, gold, bismuth, and silver) are currently used clinically for the treatment of various diseases. Integrating multiomics approaches, particularly metalloproteomics, with other biochemical characterizations enables comprehensive understanding of cellular responses of metallodrugs, which in turn will guide the rational design of a new drug and modification of the presently used drugs. This review aims to summarize the recent progress in this area. We will describe the technology platforms and their applications for uncovering the mechanisms of action of metallodrugs, for which remarkable advances have been achieved recently. Moreover, we will also highlight the application of newly generated knowledge for the development of novel therapeutic strategies. |
Persistent Identifier | http://hdl.handle.net/10722/293262 |
ISSN | 2023 Impact Factor: 6.9 2023 SCImago Journal Rankings: 2.328 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wang, H | - |
dc.contributor.author | Zhou, Y | - |
dc.contributor.author | XU, X | - |
dc.contributor.author | Li, H | - |
dc.contributor.author | Sun, H | - |
dc.date.accessioned | 2020-11-23T08:14:11Z | - |
dc.date.available | 2020-11-23T08:14:11Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Current Opinion in Chemical Biology, 2020, v. 55, p. 171-179 | - |
dc.identifier.issn | 1367-5931 | - |
dc.identifier.uri | http://hdl.handle.net/10722/293262 | - |
dc.description.abstract | Medicinal inorganic chemistry has been largely stimulated by the clinic success of platinum anticancer drugs. An array of metal-based drugs (e.g. platinum, gold, bismuth, and silver) are currently used clinically for the treatment of various diseases. Integrating multiomics approaches, particularly metalloproteomics, with other biochemical characterizations enables comprehensive understanding of cellular responses of metallodrugs, which in turn will guide the rational design of a new drug and modification of the presently used drugs. This review aims to summarize the recent progress in this area. We will describe the technology platforms and their applications for uncovering the mechanisms of action of metallodrugs, for which remarkable advances have been achieved recently. Moreover, we will also highlight the application of newly generated knowledge for the development of novel therapeutic strategies. | - |
dc.language | eng | - |
dc.publisher | Elsevier Ltd, Current Opinion Journals. The Journal's web site is located at http://www.elsevier.com/locate/cbi | - |
dc.relation.ispartof | Current Opinion in Chemical Biology | - |
dc.subject | Metalloproteomics | - |
dc.subject | Multi-omics | - |
dc.subject | Metallodrugs | - |
dc.subject | Mechanism of action | - |
dc.subject | Mechanism-driven new therapy development | - |
dc.title | Metalloproteomics in conjunction with other omics for uncovering the mechanism of action of metallodrugs: mechanism-driven new therapy development | - |
dc.type | Article | - |
dc.identifier.email | Wang, H: wanghaib@hku.hk | - |
dc.identifier.email | Zhou, Y: zy2018@connect.hku.hk | - |
dc.identifier.email | Li, H: hylichem@hku.hk | - |
dc.identifier.email | Sun, H: hsun@hku.hk | - |
dc.identifier.authority | Sun, H=rp00777 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.cbpa.2020.02.006 | - |
dc.identifier.pmid | 32200302 | - |
dc.identifier.scopus | eid_2-s2.0-85081671186 | - |
dc.identifier.hkuros | 318905 | - |
dc.identifier.volume | 55 | - |
dc.identifier.spage | 171 | - |
dc.identifier.epage | 179 | - |
dc.identifier.isi | WOS:000534347400023 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 1367-5931 | - |